Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05748600
Other study ID # AR-DEX-22-03
Secondary ID 2022-003005-30
Status Recruiting
Phase Phase 3
First received
Last updated
Start date January 30, 2023
Est. completion date April 2025

Study information

Verified date February 2024
Source Areteia Therapeutics
Contact EXHALE Recruiting
Phone 888-584-9281
Email clinicaltrials@areteiatx.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma to evaluate improvements in lung function, asthma control, and quality of life. In addition, the study will further evaluate the safety and tolerability of dexpramipexole in participants with eosinophilic asthma.


Recruitment information / eligibility

Status Recruiting
Enrollment 550
Est. completion date April 2025
Est. primary completion date March 2025
Accepts healthy volunteers No
Gender All
Age group 12 Years to 99 Years
Eligibility Inclusion Criteria: 1. Signed informed consent form and assent form, as appropriate. 2. Male or female =12 years of age at Screening Visit 1. Sites in Poland will only include participants aged =18 years. Asthma-related criteria 3. Documented physician diagnosis of asthma for =12 months prior to Screening Visit 1. 4. Participants requiring at a minimum daily low dose inhaled corticosteroids (ICS; =100 µg/day fluticasone propionate dry powder formulation daily or clinically comparable, per GINA 2021), plus one or more additional daily maintenance asthma controller medications, eg, long-acting ß2 agonist (LABA), leukotriene antagonist, theophylline, long-acting muscarinic antagonists, cromolyn/nedocromil. Note: In Poland, this will instead include participants requiring a minimum daily medium dose ICS (=500 µg/day fluticasone propionate dry powder formulation daily or clinically comparable, per GINA 2021). Use of daily ICS must be for at least 12 weeks prior to Screening Visit 1 and the doses of all controller medications must be stable for at least 4 weeks prior to Screening Visit 1. 5. Pre-BD FEV1 =40% and <80% (<90% for participants 12 to 17 years of age) of predicted at Screening Visit 2. 6. Bronchodilator reversibility, at Screening Visit 2, as evidenced by =12% and =200 mL improvement in FEV1, 15 to 30 minutes following inhalation of 400 µg (four puffs) of albuterol/salbutamol (=12% and =160 mL for ages 12 to 17).Participants who do not meet the bronchodilator reversibility inclusion criterion but have =10% and =160 mL reversibility, may repeat the reversibility spirometry assessment once during the Screening Period, at an unscheduled visit at least 7 days prior to baseline. 7. ACQ-6 =1.5 at Screening Visit 2. 8. Eosinophil count of =0.30x10?/L at Screening Visit 1. If the initial value is between 0.250x10?/L to 0.299x10?/L, then this may be repeated once at an unscheduled visit (prior to Screening Visit 2). General medical history 9. Negative urine pregnancy test for women of childbearing potential (WOCBP; after menarche) at the Screening and Baseline visits. 10. WOCBP must use either of the following methods of birth control, from Screening Visit 1 through the End of Study Visit: 1. A highly effective form of birth control (confirmed by the investigator). Highly effective forms of birth control include: true sexual abstinence, a vasectomized sexual partner, Implanon, female sterilization by tubal occlusion, any effective intrauterine device (IUD), IUD/intrauterine system (IUS), Levonorgestrel Intrauterine system, or oral contraceptive. Or 2. Two protocol acceptable methods of contraception in tandem. - Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal. Women will be considered postmenopausal if they have been amenorrheic for 12 months prior to the planned date of the Baseline Visit without an alternative medical cause. The following age specific requirements apply: 3. Women <50 years old will be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatment and follicle stimulating hormone levels in the postmenopausal range. 4. Women =50 years old will be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatment. least 7 days prior to baseline. Exclusion Criteria: Asthma-related criteria 1. A participant who experiences a severe asthma exacerbation (defined as a deterioration of asthma that results in emergency treatment, hospitalization prior to the Screening Visit 1 up to and including the Baseline Visit. Participants who experience an asthma exacerbation during the Screening/Run-in Period may remain in screening and proceed with study visits 14 days after they have completed their course of oral steroids or returned to their pre-Screening visit maintenance dose of oral steroids and the investigator considers participant has returned to baseline status. 2. Current diagnosis of diseases which may confound interpretation of this study's findings such as allergic bronchopulmonary aspergillosis, eosinophilic granulomatosis with polyangiitis, eosinophilic gastrointestinal diseases, or hypereosinophilic syndrome, or lung diseases (eg, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis). 3. Respiratory infection: Upper or lower respiratory tract, sinus, or middle ear infection within the 4 weeks before Screening Visit 1. Prohibited medications/procedures 4. Treatment with a biologic investigational drug in the last 5 months prior to Screening Visit 1. Treatment with non-biologic investigational drugs in the previous 30 days or five-half-lives prior to Screening Visit 1, whichever is longer. Treatment with GSK3511294 (long acting anti-interleukin-5) in the past 12 months. 5. Treatment with any of the following monoclonal antibody therapies within 120 days prior to Baseline: benralizumab, dupilumab, mepolizumab, reslizumab, omalizumab, tezepelumab, or tralokinumab. 6. Treatment with pramipexole (Mirapex®) within 30 days of Baseline. 7. Treatment with selected drugs known to have a substantial risk of neutropenia in the past 30 days prior to Screening Visit 1. 8. Bronchial thermoplasty procedure in the past 12 months prior to Screening Visit 1 or planned during the study period. General medical history 9. Weight <40 kg at Screening Visit 2. 10. Current smoking within 12 months prior to Screening Visit 1 or a smoking history of >10 packyears. Smoking includes tobacco, vaping, and/or marijuana use. 11. Known or suspected alcohol or drug abuse. 12. Uncontrolled severe hypertension: systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg prior to the Baseline Visit despite antihypertensive therapy. 13. History of malignancy that required surgery (excluding local and wide-local excision), radiation therapy and/or systemic therapy during the 5 years prior to the Baseline Visit. 14. History of human immunodeficiency virus (HIV) infection or chronic infection with hepatitis B or C. 15. A helminth parasitic infection diagnosed within 24 weeks prior to Screening Visit 1, that has not been treated with or has failed to respond to standard of care therapy. 16. Medical or other condition likely to interfere with participant's ability to undergo study procedures, adhere to visit schedule, or comply with study requirements. 17. Known or suspected noncompliance with medication. 18. Unwillingness or inability to follow the procedures outlined in the protocol. Clinical safety labs 19. Absolute neutrophil count <2.000x10?/L at Screening Visit 1 or Screening Visit 2.. 20. Renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2 at Screening Visit 2 (using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula [Levey et al, 2009] for age =18 years at screening; using the Bedside Schwartz [Schwartz and Work, 2009] eGFR formula for age <18). 21. Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained elevations in alanine aminotransferase (ALT), aspartate aminotransferase (AST), >3x the upper limit of normal (ULN), or total bilirubin >2x ULN at Screening Visit 2 confirmed by a repeat abnormal measurement of the relevant value(s), at least 1 week apart. Cardiac safety 22. History of New York Heart Association class IV heart failure or last known left ventricular ejection fraction <25%. 23. History of major adverse cardiovascular event (MACE) within 3 months prior to the Baseline Visit. 24. History of cardiac arrhythmia within 3 months prior to the Baseline Visit that is not controlled by medication or via ablation. 25. History of long QT syndrome. 26. Corrected QT interval by Fridericia (QTcF) interval >450 ms for males and >470 ms for females at Screening Visit 2 or QTcF =480 ms for participants with bundle branch block. 27. Clinically important abnormalities in resting ECG that may interfere with the interpretation of QTcF interval changes at Screening Visit 2, including resting heart rate <45 beats per minute (bpm) or >100 bpm. Pregnancy/Lactation 28. Pregnant women or women breastfeeding. 29. Males who are unwilling to use an acceptable method of birth control during the entire study period (ie, condom with spermicide). For this study, rescreening may only be permitted under specific circumstances and only after contact with a Sponsor Clinical representative.

Study Design


Intervention

Drug:
Dexpramipexole Dihydrochloride
administration of dexpramipexole tablet
Placebo
administration of placebo tablet

Locations

Country Name City State
Poland Research Site 40048-001 Bedzin
Poland Research Site 40048-006 Gizycko
Poland Research Site 40048-021 Katowice
Poland Research Site 40048-008 Kraków
Poland Research Site 40048-010 Piaseczno
Poland Research Site 40048-016 Poznan
Poland Research Site 40048-014 Skierniewice
Poland Research Site 40048-012 Trzebnica
Romania Research Site 40040-002 Brasov
Romania Research Site 40040-004 Brasov Brasov
Romania Research Site 40040-006 Cluj-Napoca Cluj
Romania Research Site 40040-007 Cluj-Napoca
Romania Research Site 40040-001 Constanta
Romania Research Site 40040-003 Timisoara
United Kingdom Research Site 40044-010 Altrincham
United Kingdom Research Site 40044-018 Bellshill
United Kingdom Research Site 40044-021 Birmingham
United Kingdom Research Site 40044-017 Chorley
United Kingdom Research Site 40044-022 Enfield Town
United Kingdom Research Site 40044-019 Liverpool
United Kingdom Research Site 40044-001 Manchester
United Kingdom Research Site 40044-004 Manchester
United Kingdom Research Site 40044-005 Manchester
United Kingdom Research Site 40044-006 Manchester
United Kingdom Research Site 40044-009 Manchester
United Kingdom Research Site 40044-012 Manchester
United Kingdom Research Site 40044-013 Manchester
United Kingdom Research Site 40044-013 Manchester
United Kingdom Research Site 40044-020 Manchester
United Kingdom Research Site 40044-030 Manchester
United Kingdom Research Site 40044-031 Manchester
United Kingdom Research Site 40044-032 Manchester
United Kingdom Research Site 40044-033 Manchester
United Kingdom Research Site 40044-036 Manchester
United Kingdom Research Site 40044-002 Oldham
United Kingdom Research Site 40044-024 Preston
United Kingdom Research Site 40044-026 Rochdale
United Kingdom Research Site 40044-008 Salford
United Kingdom Research Site 40044-029 Stockport
United Kingdom Research Site 40044-034 Stockport
United Kingdom Research Site 40044-063 Wigan
United States Research Site 40001-334 Allen Texas
United States Research Site 40001-068 Amarillo Texas
United States Research Site 40001-075 Augusta Georgia
United States Research Site 40001-048 Aventura Florida
United States Research Site 40001-090 Berwyn Illinois
United States Research Site 40001-005 Brandon Florida
United States Research Site 40001-051 Brandon Florida
United States Research Site 40001-340 Burke Virginia
United States Research Site 40001-343 Chicago Illinois
United States Research Site 40001-034 Cincinnati Ohio
United States Research Site 40001-353 Colorado Springs Colorado
United States Research Site 40001-032 Columbia South Carolina
United States Research Site 40001-083 Columbia Missouri
United States Research Site 40001-018 Columbus Georgia
United States Research Site 40001-029 Coral Gables Florida
United States Research Site 40001-023 Dallas Texas
United States Research Site 40001-028 Dallas Texas
United States Research Site 40001-017 Dayton Ohio
United States Research Site 40001-050 E. Amherst New York
United States Research Site 40001-363 Edison New Jersey
United States Research Site US-40001-038 Edmond Oklahoma
United States Research Site 40001-036 Elwood Indiana
United States Research Site 40001-006 Flint Michigan
United States Research Site 40001-350 Gainesville Florida
United States Research Site 40001-039 Gastonia North Carolina
United States Research Site 40001-027 Grants Pass Oregon
United States Research Site 40001-037 Grants Pass Oregon
United States Research Site 40001-014 Greenacres City Florida
United States Research Site 40001-339 Greenfield Wisconsin
United States Research Site 40001-025 Greenville South Carolina
United States Research Site 40001-047 Hawthorne New York
United States Research Site 40001-054 Hialeah Florida
United States Research Site 40001-067 Hialeah Florida
United States Research Site 40001-020 Homestead Florida
United States Research Site 40001-064 Houston Texas
United States Research Site 40001-085 Houston Texas
United States Research Site 40001-002 Kissimmee Florida
United States Research Site 40001-015 Kissimmee Florida
United States Research Site 40001-357 Lancaster California
United States Research Site 40001-366 Lilburn Georgia
United States Research Site 40001-086 Loxahatchee Groves Florida
United States Research Site 40001-318 Maitland Florida
United States Research Site 40001-313 Marrero Louisiana
United States Research Site 40001-001 Miami Florida
United States Research Site 40001-024 Miami Florida
United States Research Site 40001-026 Miami Florida
United States Research Site 40001-059 Miami Florida
United States Research Site 40001-065 Miami Florida
United States Research Site 40001-066 Miami Florida
United States Research Site 40001-338 Miami Beach Florida
United States Research Site 40001-362 Mission Viejo California
United States Research Site 40001-043 Newport Beach California
United States Research Site 40001-062 Newport Beach California
United States Research Site 40001-348 Ocala Florida
United States Research Site 40001-079 Oklahoma City Oklahoma
United States Research Site 40001-019 Owensboro Kentucky
United States Research Site 40001-333 Pleasant View Utah
United States Research Site 40001-337 Portland Oregon
United States Research Site 40001-304 Red Oak Texas
United States Research Site 40001-135 River Forest Illinois
United States Research Site 40001-074 Saint Charles Missouri
United States Research Site 40001-046 Saint Louis Missouri
United States Research Site 40001-069 Saint Petersburg Florida
United States Research Site 40001-377 San Antonio Texas
United States Research Site 40001-088 San Jose California
United States Research Site 40001-073 Spartanburg South Carolina
United States Research Site 40001-335 Sugar Land Texas
United States Research Site 40001-322 Surprise Arizona
United States Research Site 40001-370 Tallahassee Florida
United States Research Site 40001-004 Tampa Florida
United States Research Site 40001-063 Toledo Ohio
United States Research Site 40001-359 Upland California
United States Research Site 40001-319 Viera Florida
United States Research Site 40001-372 Warren Michigan
United States Research Site 40001-003 West Covina California
United States Research Site 40001-055 White Marsh Maryland

Sponsors (1)

Lead Sponsor Collaborator
Areteia Therapeutics

Countries where clinical trial is conducted

United States,  Poland,  Romania,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in pre-BD FEV1 from baseline Pre-bronchodilator forced expiratory volume (pre-BD) FEV1, absolute change from baseline, averaged over Weeks 20 and 24. Day 1 (baseline, pre-dose), Weeks 20, 24
Secondary Change from baseline in Asthma Control Questionnaire-6 (ACQ-6) Change from baseline in Asthma Control Questionnaire-6 (ACQ-6) averaged over visits at Weeks 20 and 24. Day 1 (baseline, pre-dose), Weeks 20, 24
Secondary Change in Standardized version of the Asthma Quality of Life Questionnaire for 12 years and older (AQLQ+12) from baseline to Week 24. Day 1 (baseline, pre-dose) through Week 24
Secondary Change from baseline absolute eosinophil count (AEC) averaged across Weeks 20 and 24. Day 1 (baseline, pre-dose) through Week 24
Secondary Change from baseline forced vital capacity (FVC) averaged over Weeks 20 and 24. Day 1 (baseline, pre-dose), Weeks 20, 24
Secondary Change from baseline forced vital capacity (FVC) at Weeks 4, 8, 12, 16, 20, and 24. Day 1 (baseline, pre-dose), Weeks 4, 8, 12, 16, 20, and 24
Secondary Change from baseline post-bronchodilator (post-BD) forced expiratory volume (FEV1) at Week 24. Day 1 (baseline, pre-dose) through Week 24
Secondary The EuroQol 5-dimensional questionnaire (EQ-5D-5L) change from baseline to Week 24 Day 1 (baseline, pre-dose) through Week 24
See also
  Status Clinical Trial Phase
Completed NCT04742504 - Interaction Between Benralizumab and Basophils in Eosinophilic Asthma
Recruiting NCT04565483 - Predictive Signature of Benralizumab Response Phase 4
Completed NCT04181190 - Effects of Anti-IL5 Biological Treatments on Blood IgE Levels in Severe Asthmatic Patients
Recruiting NCT05787678 - Dupilumab Efficacy on Bronchial Inflammation, Small Airways Disfunction and Mucous Secretion
Completed NCT04456270 - Asthma Control in a Dutch Primary Care Population
Not yet recruiting NCT05091385 - Efficacy of Mepolizumab in Polish Patients With Severe Eosinophilic Asthma
Recruiting NCT05078281 - Patients With Severe Eosinophilic Asthma Treated With Benralizumab
Recruiting NCT04512521 - Functional Lung MRI for Early Treatment Response Assessment for Patients With Eosinophilic Asthma
Recruiting NCT05813288 - A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Phase 3
Recruiting NCT04319705 - Anti-viral Effects of Azithromycin in Patients With Asthma and COPD Phase 4
Recruiting NCT06288516 - BenRalizumab Effect on Airway Remodeling in Severe asTHma Phase 4
Active, not recruiting NCT03733535 - Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI N/A
Not yet recruiting NCT05241769 - The Influence of Inhaled CorticoSteroids Adherence on Treatment Response to Mepolizumab in Severe Eosinophilic Asthma
Not yet recruiting NCT04924478 - Evaluation of Volatile Organic Compounds in Mepolizumab Therapy
Recruiting NCT05763121 - A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma. Phase 3
Completed NCT03453021 - Effect of Mepolizumab on Decrease of Systemic Corticosteroids in Patients With Severe Eosinophilic Asthma
Active, not recruiting NCT04612556 - Efficacy of Mepolizumab in Severe Asthmatics on a Long Term (MESILICO)
Recruiting NCT05404763 - Mepolizumab and Physical Activity in Severe Asthma
Completed NCT04710134 - Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma Phase 4
Not yet recruiting NCT05144087 - The Influence of Mepolizumab on Structural and Inflammatory Cells in Severe Eosinophilic Asthma